argenx presents new VYVGART data for argenx stock

Published on 10/01/2026 at 10:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

argenx stock costs EUR 841.50 on October 1, 2026 after EUR 845.90, minus 0.52 percent. Goldman Sachs lifted its target to EUR 982 from EUR 973.

Fotorealistisches Laborpanorama: Wissenschaftler in weißen Kitteln begutachten leuchtende Antikörper-3D-Modelle auf Bildschirmen, Stahltische mit Laborgeräten im Hintergrund — Argenx NL0010832176 Forscher analysieren im modernen Biopharma-Labor leuchtende Antikörper-Strukturen auf großen Monitoren, Illustration mit AI erstellt.

argenx stock was trading at EUR 841.50 at Lang & Schwarz on October 1, 2026 at 10:06 a.m. CEST, down 0.52 percent from the prior close of EUR 845.90. The company presented new VYVGART data and pipeline updates at neuromuscular disease meetings on September 29, 2026, according to argenx.

New VYVGART data expands the story

The September 29 release covered VYVGART and VYVGART HYTRULO data in generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. The meeting program also included empasiprubart and adimanebart, giving investors a view of development work beyond the company's leading franchise.

A separate filing cited real-world data from more than 1,100 U.S. myasthenia gravis patients treated with VYVGART. The analysis reported improvements in MG-ADL scores, steroid burden and exacerbation rates across patient subgroups, according to StockTitan.

Goldman target reaches EUR 982

Goldman Sachs raised its Argenx price target from EUR 973 to EUR 982 on September 25, 2026, while keeping a Buy rating. Analyst Rajan Sharma pointed to potential upside in market expectations for VYVGART in the low to mid-single-digit percentage range, as reported by FinanzNachrichten.

TradingView reported on October 1, 2026 that the average 12-month target from 24 analysts rose from USD 1,198.68 to USD 1,205.94. Its coverage also showed 24 Buy ratings, four Holds and no Sell ratings among 28 covering analysts, keeping the analyst backdrop positive despite the lower euro quote.

Revenue growth sets the next test

At a September 14 investor conference, argenx described 17 percent sequential revenue growth from the first quarter to the second quarter of 2026 and 18 consecutive quarters of expansion since VYVGART launched. The company also highlighted EUR 5.2 billion in cash at the end of the previous quarter, according to Investing.com.

The next scheduled earnings date is October 22, 2026. That date places the upcoming report close to the market's current debate: whether VYVGART can keep expanding while newer indications and pipeline assets add a second growth engine.

The euro quote remains below EUR 845.90

At Lang & Schwarz, argenx stock stood at EUR 841.50 on October 1, 2026 at 10:06 a.m. CEST, down 0.52 percent versus the EUR 845.90 prior close. Market capitalization was USD 59.6 billion as of September 30, 2026, while the latest U.S. quote showed a 52-week range of USD 661.85 to USD 1,072.75.

The further course of trading is shown by the continuously updated real-time quote of argenx stock.